Pharma & Biotech

BridgeBio Pharma has captured significant attention following compelling long-term data presented at the European Society of Cardiology congress. The biopharmaceutical...

Ocugen has achieved a critical regulatory milestone after European Medicines Agency (EMA) officials endorsed the company's development strategy for its...

Despite reporting progress in its pivotal Phase 3 trial for a hepatitis C combination therapy, Atea Pharmaceuticals Inc. witnessed its...

Autolus Therapeutics presents investors with a compelling puzzle. The clinical-stage biopharmaceutical company boasts a recently approved cancer therapy and impressive...

PepGen Inc. finds itself navigating a perfect storm of declining investor confidence, legal challenges, and a strategic pipeline overhaul. The...

Enzo Biochem Inc. has concluded its tenure as a publicly traded company following its full acquisition by the private equity...

The investment narrative surrounding transplant diagnostics firm CareDx is one of stark contrasts. The company’s latest quarterly results revealed significant...

While Electrocore's stock has experienced significant downward pressure in recent months, a notable consensus persists among market analysts. All eight...

Shares of clinical-stage biopharmaceutical company IO Biotech concluded Friday's trading session unchanged at $1.58, following a volatile period that saw...

Aldeyra Therapeutics has announced significant regulatory progress for its two leading pharmaceutical candidates, ADX-2191 and reproxalap. These developments position the...